Actinium Pharmaceuticals, Inc. (ATNM) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+0.8%

$1.48

vs $1.47 price

Levered DCF

$1.48

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

-8.02

Distress zone

Rating

S-

Overall 5 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-1.25×	-0.99×	-2.78×	-7.77×	-5.01×	-4.26×	-1.49×	-1.74×
P/B	5.42×	1.16×	3.72×	3.87×	1.68×	1.54×	5.76×	4.66×
P/S	471.4×	0×	1,668.5×	249.62×	108.05×	0×	0×	0×
EV / EBITDA	0.12×	0.89×	-1.26×	-4.67×	-1.9×	-1.46×	-1.15×	-1.16×
Gross margin	100.0%	0.0%	100.0%	100.0%	54.2%	0.0%	0.0%	0.0%
Operating margin	-40274.4%	0.0%	-64098.8%	-3311.1%	-2182.2%	0.0%	0.0%	0.0%
Net margin	-37652.2%	0.0%	-60269.1%	-3205.5%	-2165.6%	0.0%	0.0%	0.0%
Current ratio	6.2×	9.14×	9.21×	10.44×	11.66×	13.62×	1.89×	2.36×
Debt / equity	0.22×	0.05×	0.06×	0.04×	0×	0.01×	0.25×	0.03×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	-137.44×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	-0.0%	-0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-432.6%	-116.7%	-134.2%	-49.7%	-33.7%	-36.2%	-388.0%	-268.4%
Return on invested capital	-81.4%	-60.8%	-70.6%	-32.8%	-33.8%	-36.1%	-312.1%	-262.5%
Return on assets	-65.5%	-49.7%	-59.9%	-28.9%	-30.8%	-33.5%	-187.6%	-158.9%
Free cash flow yield	-58.2%	-87.3%	-35.1%	3.2%	-17.0%	-23.1%	-66.2%	-50.4%
Earnings yield	-79.9%	-100.9%	-36.1%	-12.8%	-20.0%	-23.5%	-67.4%	-57.6%
Enterprise value	-$3.9M	-$33.4M	$60.6M	$150.8M	$46.1M	$31.8M	$24.7M	$27.6M
Net debt / EBITDA	1.4×	1.91×	1.55×	3.29×	3.2×	2.89×	0.36×	0.56×
Cash conversion cycle (days)	0	-3,406	0	0	-3,855	-3,544	-3,995	-41,839